Yttrium-90 Ibritumomab Tiuxetan Followed by Rituximab Maintenance as Treatment for Patients with Diffuse Large B-Cell Lymphoma Are Not Candidates for Autologous Stem Cell Transplant
Jon Arnason(Beth Israel Deaconess Medical Center), Robin Joyce(Beth Israel Deaconess Medical Center), Katarina Luptakova(Tesaro (United States)), Jefferson Parker, Dimitrios Tzachanis(Dana-Farber Cancer Institute), Michelle Kim(University of North Carolina at Chapel Hill), David Avigan(Beth Israel Deaconess Medical Center), Barbara Grant(University of Vermont), Jeffrey I. Zwicker(Memorial Sloan Kettering Cancer Center), James D. Levine(Beth Israel Deaconess Medical Center), Jacalyn Rosenblatt(Beth Israel Deaconess Medical Center)
Cited by 11
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma
|Journal of Clinical Oncology|2002|1.2k
Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
|New England Journal of Medicine|2011|1.1k
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
|Journal of Clinical Oncology|2012|1.1k